Qualitest Launches Generic Singulair®

HUNTSVILLE, Ala., Aug. 6, 2012 /PRNewswire/ -- Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity.  Qualitest will begin shipping the product immediately.   Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis. 

The total combined sales for Montelukast Sodium Tablets and Chewables in the U.S. for the 12 months ending June 30, 2012, were approximately $4.9 billion, according to IMS Health.

About Qualitest
Founded in 1983, Qualitest provides affordable, high-quality generic pharmaceuticals. Featuring a current portfolio exceeding 600 products, the company has grown significantly since its inception and is now ranked in the top ten among all suppliers of generics, based on total prescriptions filled. Qualitest is an operating company of Endo Health Solutions Inc. (NASDAQ: ENDP) a US-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike. Learn more at www.endo.com.  

SOURCE Qualitest Pharmaceuticals

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.